In vitroassessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis

Abstract

F508del-CFTR, the most common disease-associated mutation in cystic fibrosis, may lose its responsiveness to the CFTR potentiator ivacaftor upon prolonged exposure to the newly developed CF drug Trikafta https://bit.ly/3A22MKQ Cite this article as: Yeh H-I, Hwang T-C. In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis.